Phathom Pharmaceuticals (PHAT) Operating Income (2022 - 2025)
Historic Operating Income for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$15.3 million.
- Phathom Pharmaceuticals' Operating Income rose 7842.96% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.5 million, marking a year-over-year increase of 2585.74%. This contributed to the annual value of -$277.5 million for FY2024, which is 6583.81% down from last year.
- According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Operating Income is -$15.3 million, which was up 7842.96% from -$59.9 million recorded in Q2 2025.
- Phathom Pharmaceuticals' Operating Income's 5-year high stood at -$15.3 million during Q3 2025, with a 5-year trough of -$78.9 million in Q1 2025.
- Over the past 4 years, Phathom Pharmaceuticals' median Operating Income value was -$46.6 million (recorded in 2022), while the average stood at -$51.4 million.
- Per our database at Business Quant, Phathom Pharmaceuticals' Operating Income tumbled by 14384.09% in 2024 and then surged by 7842.96% in 2025.
- Over the past 4 years, Phathom Pharmaceuticals' Operating Income (Quarter) stood at -$46.6 million in 2022, then crashed by 49.81% to -$69.9 million in 2023, then grew by 14.97% to -$59.4 million in 2024, then surged by 74.3% to -$15.3 million in 2025.
- Its Operating Income stands at -$15.3 million for Q3 2025, versus -$59.9 million for Q2 2025 and -$78.9 million for Q1 2025.